By Giulia Petroni 
 

Roche Holding AG on Monday said that its phase 3 study on the use of Polivy in combination with chemotherapy regimen R-CHP for the treatment of diffuse large B-cell lymphoma met its primary endpoint.

The Swiss pharmaceutical giant said the trial showed the use of polatuzumab vedotin with rituximab plus cyclophosphamide, doxorubicin and prednisone significantly improves outcomes in patients with a previously untreated aggressive form of lymphoma compared with standard of care.

Roche said results of the study will be submitted to health authorities.

 

Write to Giulia Petroni at giulia.petroni@wsj.com

 

(END) Dow Jones Newswires

August 09, 2021 02:43 ET (06:43 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Roche (QX) Charts.